Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-25
2010-11-30
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S432000, C514S451000, C546S242000, C549S028000, C549S416000
Reexamination Certificate
active
07842705
ABSTRACT:
The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.
REFERENCES:
patent: 3114775 (1963-12-01), Hughes et al.
patent: 3515559 (1970-06-01), Wayne et al.
patent: 3897420 (1975-07-01), Krapcho et al.
patent: 3911129 (1975-10-01), Krapcho et al.
patent: 3994880 (1976-11-01), Krapcho et al.
patent: 4127667 (1978-11-01), Rovnyak
patent: 4415621 (1983-11-01), Specht et al.
patent: 4755450 (1988-07-01), Sanders et al.
patent: 4987057 (1991-01-01), Kaji et al.
patent: 5700804 (1997-12-01), Collins et al.
patent: 5811218 (1998-09-01), Kaji et al.
patent: 5852018 (1998-12-01), Bryans et al.
patent: 6022597 (2000-02-01), Yan et al.
patent: 2002/0006966 (2002-01-01), Arbiser
patent: 03/44643 (1991-02-01), None
patent: WO-01/46110 (2001-06-01), None
Artico, et al., “Geometrically and Conformationally Restrained Cinnamoyl Compounds as Inhibitors of HIV-1 Integrase: Synthesis, Biological Evaluation, and Molecular Modeling,”J. Med. Chem., 1998, pp. 3948-3960, vol. 41, No. 21.
Buu-Hoi et al.,Bulletin de la Societe Chimque de France, 12, 3096-3099, 1964, CA 62: 66406, 1965.
Buu-Hoi et al.,Compt. Rend.251, 2725-2727, 1960, CA 55: 112072, 1960.
Chen et al.,Thromb, Haemost.86(1): 334-345, 2001.
Cremlyn et al., “The Synthesis and Chlorosulfonation of Some Diarylidene and Heteroarylidene Ketones with Varying Alicyclic Ring Size”,Phosphorus, Sulfur, and Silicon, 1995, pp. 205-217, vol. 107.
Desiraju et al., “A Convenient Preparation of Substituted 2,5-Dibenzylidenecyclopent-3-en-1-ones,”Indian Journal of Chemistry, 1988, pp. 953-954, vol. 27B, No. 10.
Dimmock et al., “Evaluation of Some N-Acyl Analogues of 3,5-Bis(arylidene)-4-Piperidones for Cytotoxic Activity,”Drug Design and Discovery, 1992, vol. 8, pp. 291-299.
Dimmock et al., “Cytotoxic Evaluation of Some 3,5-Diarylidene-4-piperidones and Various Related Quaternary Ammonium Compounds and Analogs,”Journal of Pharmaceutical Sciences, 1994, pp. 1124-1130, vol. 83, No. 8.
Dinkova-Kostova, et al., “Chemoprotective Properties of Phenylpropenoids, Bis(benzylidene)cycloalkanones, and Related Michael Reaction Acceptors: Correlation of Potencies as Phase 2 Enzyme Inducers and Radical Scavengers,”J. Med. Chem., 1998, pp. 5287-5296, vol. 41, No. 26.
El-Subbagh, et al., “Synthesis and Biological Evaluation of Certain α,β-Unsaturated Ketones and Their Corresponding Fused Pyridines as Antiviral and Cytotoxic Agents,”J. Med. Chem., 2000, pp. 2915-2921, vol. 43, No. 15.
Fujisaki, et al., JP 62225562, 1988 (CA 108:77360).
Gutkowska,Poloniae Pharmaceutica, 1973, pp. 361-364, vol. 30, No. 4.
Gutkowska, et al.,Acta Poloniae Pharmaceutica, 1985, pp. 437-441, vol. 42, No. 5 (CA 107:115819).
Gutkowska, et al.,Acta Poloniae Pharmaceutica, 1989, pp. 212-218, vol. 46, No. 3 (CA 112:216649).
Hammam, et al., “Synthesis and Anti-Cancer Activity of Pyridine and Thiazolopyrimidine Derivatives Using 1-Ethylpiperidone as a Synthon,”Indian J. Chem., 2001, pp. 213-221, vol. 40B.
Katritzky et al., “Bridged Cyanine Dyes. Part 3 [1]. Zwitterionic Bis-4-pyridyl and Cationic Bis-dimethylanilino Derivatives,”Journal of Heterocyclic Chemistry, 1988, pp. 1321-1325, vol. 25, No. 5.
Keinan, et al.,J. Org. Chem., 1983, pp. 5302-5309, vol. 48, No. 26.
Leonard et al., “γ-Pyrones by Isomerizaton. Substituted 3,5-Dibenzy1-4H-pyran-4-ones,”Journal of the American Chemical Society, 1957, pp. 156-160, vol. 79, No. 1.
Li, et al., “Samarium (III) Iodide Promoted Preparation of α,α'—bis(substituted benzylidene) cyclohexanones from Benzaldehydes and Cyclohexanone,”J. Chem, Research(S), 2000, pp. 580-581.
Mahfouz, et al., “Synthese mehrfach oxigenierter 2-Hydroxyxanthone,”Arch. Pharm.(Weinheim), 1990, pp. 163-169, vol. 323.
Nakano, et al., “A Convenient Synthesis of α,α'—Bis(substitutedbenzylidene)cycloalkanones,”Chemistry Letters, 1993, pp. 2157-2158.
Ojima, et al.,Bull. Chem. Soc. Jpn., 1977, pp. 1522-1526, vol. 50, No. 6 (CA 87:20055).
Pivnenko, et al.,Zh. Org. Khim, 1972, pp. 1096-1102, vol. 42, No. 5 (CA 84:513251).
Pivnenko, et al.,Zh. Org. Khim, 1975, pp. 2527-2533, vol. 11, No. 12 (CA 84:73234).
Shoppee, et al.,J. Chem. Soc. Perkin Trans I, 1977, pp. 1028-1030, vol. 9 (CA 87:102029).
Sun, et al., “Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases,”J. Med. Chem., 1999, pp. 5120-5130, vol. 42, No. 25.
Sun, et al., “Identification of Substituted 3-[(4,5,6,7-Tetrahydro-1H-indo1-2-yl)methylene]-1,3-dihydroindol-2-ones as Growth Factor Receptor Inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ Tyrosine Kinases,”J. Med. Chem., 2000, pp. 2655-2663, vol. 43, No. 14.
Sun, et al., “Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases,”J. Med. Chem., 1998, pp. 2588-2603, vol. 41, No. 14.
Teuscher, “Potentiell antiangiogene Substanzen aus der Gruppe der α, α'—Bis(amidinobenzyl)cycloalkanon-Derivate and α-(Arylsulfonylamino)-ω-phenylcarbonsäure-4- amidinoanilide,”Pharmazie, 1987, pp. 109-110, vol. 42, H.2.
Thaloor, et al.,“Inhibition of Angiogenic Differentiation of Human Umbilical Vein Endothelial Cells by Curcumin,”Cell Growth&Differentiation, 1998, pp. 305-312, vol. 9.
Vieth, et al., “DoMCoSAR: A Novel Approach for Establishing the Docking Mode That Is Consistent with the Structure-Activity Relationship. Application to HIV-1 Protease Inhibitors and VEGF Receptor Tyrosine Kinase Inhibitors”,J. Med. Chem., 2000, pp. 3020-3032, vol. 43, No. 16.
Wiemer et al., “Vidalols A and B, New Anti-Inflammatory Bromophenols from the Caribbean Marine Red AlgaVidalia obtusaloba,” Experientia, 1991, pp. 851-853, vol. 47.
Zheng, et al.,Zhongguo Yiyao Gonye Zazhi, 1997, p. 230231, vol. 28, No. 5 (CA 115:102878).
Adams Brian
Davis Matthew C.
Ferstl Eva M.
Liotta Dennis C.
Shoji Mamoru
Alston & Bird LLP
Balasubramanian Venkataraman
Emory University
LandOfFree
Curcumin analogs with anti-tumor and anti-angiogenic properties does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Curcumin analogs with anti-tumor and anti-angiogenic properties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Curcumin analogs with anti-tumor and anti-angiogenic properties will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183473